rawfin.tv
Zacks Research Upgrades Theravance Biopharma to Strong-Buy
AnalysisstocksAI Generated

Zacks Research Upgrades Theravance Biopharma to Strong-Buy

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Zacks Research has upgraded Theravance Biopharma (NASDAQ:TBPH) to a "Strong-Buy" rating. This upgrade follows a review of the company's prospects and recent performance.

TBPHAnalyst RatingBiopharmaHealthcareZacks

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks